A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.

D. Mcmeekin,M. Sill,K. Darcy,D. Stearns-Kurosawa,K. Webster,S. Waggoner,D. Benbrook
DOI: https://doi.org/10.1016/J.YGYNO.2007.05.013
IF: 5.304
2007-09-01
Gynecologic Oncology
Abstract:
What problem does this paper attempt to address?